ResearcherFirst Affiliated Hospital of Zhengzhou UniversityActive in the last 2 years

Bing Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3597-7861; OpenAlex author ID A5100443104. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Hypermethylated CACNB2 Predicts Poor Prognosis And Promotes Proliferation, Invasion and Apoptotic Resistance in Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-5358116/v1 ↗
Comprehensive Analysis of the Prognosis of S100 Family Members and Their Relationship with Tumor-Infiltrating Immune Cells in Human Pancreatic Adenocarcinoma First author DOI 10.21203/rs.3.rs-841869/v2 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiya Jia · 1 shared paper, 2024 · strength 0.24
- Paper Hypermethylated CACNB2 Predicts Poor Prognosis And Promotes Proliferation, Invasion and Apoptotic Resistance in Pancrea… DOI 10.21203/rs.3.rs-5358116/v1 ↗
Feng Xu · 1 shared paper, 2022 · strength 0.22
- Paper Comprehensive Analysis of the Prognosis of S100 Family Members and Their Relationship with Tumor-Infiltrating Immune Ce… DOI 10.21203/rs.3.rs-841869/v2 ↗
Yajun Ren · 1 shared paper, 2022 · strength 0.22
- Paper Comprehensive Analysis of the Prognosis of S100 Family Members and Their Relationship with Tumor-Infiltrating Immune Ce… DOI 10.21203/rs.3.rs-841869/v2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.